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Notwithstanding compelling contribution of NF-kB to the progression of osteoporosis has been re-
ported, little is known regarding direct inhibition of NF-kB beneﬁting osteoporosis. In this study,
therefore, we evaluated the role of celastrol, an NF-kB inhibitor, in a mouse model of secondary
osteoporosis. Animals were divided into three groups as Sham (control), SO (secondary osteoporosis)
and SO þ CA (secondary osteoporosis treated with celastrol). Signiﬁcant decreases in body weight and
body fat were observed following celastrol treatment in SO group, but leptin levels were much higher.
Celastrol also exhibited a signiﬁcant decrease in urinary calcium excretion. Moreover, other important
events were observed after celastrol treatment, covering substantial decrements in serum concen-
trations of PTH, TRAP-5b, CTX and DPD, improved structure of articular cartilage and cancellous bone
(revealed by H&E and safranin-O staining), and signiﬁcant decline in levels of NF-kB (P65), MMP-1, and
MMP-9. These ﬁndings demonstrated that celastrol treatment not only improved abnormal lipid
metabolism and hypercalciuria in mice subjected to secondary osteoporosis, but also ameliorated
articular cartilage lesions. Our results provided evidence of targeted therapy for NF-kB in the clinical
treatment of secondary osteoporosis.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Osteoporosis, a common age-related disease characterized by
bone loss and bonemicroarchitecture deterioration, predominantly
affects postmenopausal women (1e3). Primary osteoporosis results
from bone loss associated with normal aging, but secondary oste-
oporosis arises as a result of underlying disorders or medication
treatments (4,5). It is generally agreed that hypercalciuria is linked
to reduced bone density in osteoporotic patients, especially in
postmenopausal women (6,7). A few studies have addressed a
detrimental effect of osteoporosis on articular cartilage, suggesting
a possible link between osteoporosis and articular cartilage lesions
(8,9). A study using a mouse model of periodontitis revealed the
relation between lipopolysaccharide-induced bone loss and in-
ﬂammatory reaction (10). Accumulating knowledge on theics, YangPu Hospital, TongJi
anghai, 200090, People's Re-
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).pathological mechanisms of osteoporosis also suggested a potential
role of inﬂammatory response in the progression of secondary
osteoporosis (11,12).
NF-kappa B (NF-kB), a well-known transcription factor, is an
attractive therapeutic target for immune-related diseases due to
a pivotal role in regulation of genes that are involved in in-
ﬂammatory reaction, such as proinﬂammatory cytokines, adhe-
sion molecules and chemokines (13e15). Li also uncovered the
contribution of NF-kB to the progression of osteoporosis induced
by type Ⅱ diabetes (16). To date, many agents have been
attempted for the clinical treatment of some inﬂammatory dis-
ease, in view of the anti-inﬂammatory activity of pharmacolog-
ical suppression of NF-kB (17e22). Although great advance in
pharmacological management of osteoporosis, we still need to
explore new agents to lower osteoporotic fractures for better
quality of life in the elderly. Celastrol, an NF-kB inhibitor, exerts
powerful effects on the treatment of rheumatoid arthritis,
chronic inﬂammation, and neurodegenerative diseases because
of its anti-inﬂammatory activity (23,24), even more, celastrol has
been reported as a leptin sensitizer, and a promising agent in the
drug therapy for obesity (25), but the knowledge of it's role innese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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the possible effects of celastrol on secondary osteoporosis,
therefore, in the present study, we evaluated lipid metabolism
and calcium content following celastrol treatment in a mouse
model of secondary osteoporosis, as well as bone metabolism
and bone structure.
2. Materials and methods
2.1. Animal experiments and drug administration
Six-week-old male mice (C57BLKS/J), each weighing ranged
between 20 and 22 g, were purchased from the Jackson Laboratory
(Sacramento, CA, USA). The mice were given free access to food and
water and were caged individually under controlled temperature
(21e25 C) and humidity (50e60%) with an artiﬁcial light cycle. The
animal protocol was approved by the Committee on the Ethics of
Animal Experiments of TongJi University. Animals were grouped
into three as Sham (control), SO (secondary osteoporosis) and
SO þ CA (secondary osteoporosis treated with celastrol). Sham
group received normal feed; SO group were injected into the intra-
articular space of the right knee daily with 5mg/kg dexamethasone
(Sigma, St. Louis, MO, USA) for 8 weeks; SO þ CA group were
injected daily with a dose of 1 mg/kg celastrol (Sigma, St. Louis, MO,
USA).
In addition, for leptin administration, Sham group were divided
into three groups: Sham, Sham þ Leptin, Sham þ LA. Sham group
were injected with saline as control; Sham þ Leptin group received
intraperitoneal injection with 0.1 mg/kg/day leptin for 1 week;
Sham þ LA group were injected with 20 mg/kg pegylated super-
active mouse leptin antagonist (PEG-SMLA) every other day for 4
weeks. So did SO and SO þ CA group. The puriﬁcation, and
monopegylation of PEG-SMLA were performed as described pre-
viously (26).
2.2. Measurement by dual energy X-ray absorptiometry (DEXA)
The mice were anesthetized with 0.14 mg/kg medetomidine
(Domitor, Orion Corporation, Espoo, Finland) to measure body
weight, and % body fat was measured by DEXA (Lunar Prodigy, GE
Healthcare, Germany) as described before (27).
2.3. Serum calcium and urinary calcium
Serum calcium concentrations were determined in a Technicon-
SMAC (Technicon Instruments Corp, Tarrytown, NY). Urinary cal-
cium was measured on 24-h collections by atomic absorption
spectrophotometry. An individual was considered hypercalciuric
when the 24-h urinary calciumvaluewasS0.1mmol/kg per day on
the 20 mmol/day calcium intake.
2.4. Serum biochemical markers of bone and energy metabolism
Anesthetized mice were placed in a euthanasia chamber.
Directly after aspiration, the blood was transferred to plain
tubes. Serum was centrifuged for 1 min and stored 80 C until
analysis. The serum concentrations of leptin and PTH were
assayed at Novartis Pharma Ag with a Luminex 200™ Multi-
plexing Instrument as described earlier (28). Serum TRAP-5b and
ALP-b were measured according to the manufacturer's in-
structions using an ELISA kit (Linco Research, St. Charles, MO,
USA). Serum CTX was detected by an Elecsys b-CrossLaps™
serum assay (Roche Diagnostics) (29). Serum DPD was measured
by high-performance liquid chromatography (HPLC) as described
previously (30).2.5. Histomorphological analysis
The cartilage and cancellous bone samples were dissected
along the axial plane into pieces of 10 mm  5 mm  7 mm
with a thin layer of subchondral bone and were ﬁxed in 4%
formaldehyde for over 24 h in room temperature. After being
decalciﬁed in 10% ethylene diamine tetraacetic acid (EDTA)
solution for over 2 weeks, the samples were embedded in
parafﬁn. The specimens were cut into 4 mm thick sections and
stained with hematoxylin-eosin (H&E) and safranin-O. We used
the structure score according to Mankin histological grading
system (31) to evaluate cartilage and cancellous bone degra-
dation. Moreover, cartilage tissues were carefully dissected
under a dissecting microscope. The articular surface of each
specimen was rinsed with phosphate-buffered saline (PBS). The
cartilage surfaces of the femoral condyle and the tibial plateau
were examined with a microscope. In addition, chondrocytes
were obtained as reported earlier (32), likewise, we also per-
formed safranin-O staining to evaluate the structure of chon-
drocytes, and used Mankin histological grading system to assess
cell score.2.6. RNA isolation and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells with Trizol reagent, and
further reﬁned by an RNeasy Mini kit (Qiagen, Valencia, CA,
USA). Quantitative RT-PCR was performed as reported earlier
(33), with some alternations. b-actin was used as the internal
control. Primescript RT reagent Kit (Promega, Madison, WI, USA)
was used to synthesize cDNA. QRT-PCR reactions were per-
formed using a SYBR Green-containing PCR kit (GenePharma,
Shanghai, China). The primers of NF-kB (P65), MMP-1, MMP-9,
and b-actin were designed according to Kim et al. (33) and
Venugopal et al. (34). The relative gene expression was calcu-
lated using 2DDCt method.2.7. Western blotting
Western blotting was performed as described previously (33).
Brieﬂy, total proteins were extracted from cartilage tissue and
chondrocytes using a commercial nuclear extraction kit in
accordance with the manufacturer's instructions (Active Motif,
Carlsbad, CA). Under denaturing conditions, proteins (35 mg)
were separated by 10% SDS-PAGE mini-gel and transferred to a
polyvinylidene diﬂuoride (PVDF) membrane (Millipore, Bedford,
MA, USA) for 60 min at 100 V. After incubation in blocking buffer
(Tris-buffered saline containing 150 mM NaCl, 50 nM Tris, 0.05%
Tween-20, pH 7.5) for 1 h at room temperature, the membrane
was hybridized in blocking buffer with speciﬁc primary anti-
bodies against NF-kB (P65), MMP-1, MMP-9, and b-actin antibody
(Santa Cruz, USA) overnight at 4 C, then incubated with sec-
ondary antibodies labeled with horseradish peroxidase (HRP),
followed by a detection with chemiluminescence (ECL) reagent
(Amersham, Buckinghamshire, UK).2.8. Statistical analysis
All experiments were carried out at least three times. Data were
presented as mean ± standard error of the mean (SEM). Multiple
comparisons were performed using the KruskaleWallis test with
Bonferroni correction, followed by a ManneWhitney U-test using
SPSS 10.0 (SPSS, USA). P < 0.05 was considered statistically
signiﬁcant.
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3.1. Effects of celastrol on lipid metabolism in experimental mice
In view of the known role of NF-kB in controlling feeding
behavior (35), we detected body weight and body fat among the
three groups. As shown in Fig. 1A and B, SO þ CA group exhibitedFig. 1. Effects of celastrol on lipid metabolism in experimental mice (A) body weight
(B) body fat (C) leptin level. The data are shown as means ± SEM. *indicates a
statistically signiﬁcant difference between Sham group and SO group (P < 0.05).
#indicates a statistically signiﬁcant difference between SO group and SO þ CA group
(P < 0.05).signiﬁcantly lower body weight and body fat, relative to SO group.
Moreover, increase levels of leptin were observed following
celastrol treatment (Fig. 1C). Considering the direct inﬂuence of
leptin on body weight and body fat in experimental mice
(Supplementary Fig. 1A and B), and leptin has been reported to act
as a crucial regulator of lipid metabolism (36), thus, the results
in Fig. 1 suggested that celastrol may alleviate abnormal lipid
metabolism, induced by dexamethasone, through regulating
leptin levels.3.2. Effects of celastrol on serum calcium and urinary calcium in
experimental mice
We next examined calcium content between Sham, SO, and
SO þ CA groups, including serum calcium and urinary calcium.
Fig. 2A illustrates a notable decrease in serum calcium content after
celastrol treatment, but the signiﬁcant difference among three
groups belonged to the normal ﬂuctuation range (8e12 mg/dL). On
the other hand, urinary calcium secretion in celastrol-treated group
was signiﬁcantly lower than secondary osteoporosis group, a sta-
tistically signiﬁcant difference (Fig. 2B). These ﬁndings indicated
that hypercalciuria was improved in mice with secondary osteo-
porosis after celastrol treatment.Fig. 2. Effects of celastrol on serum calcium and urinary calcium excretion in experi-
mental mice (A) serum calcium: a statistically signiﬁcant decrease in serum calcium
content was observed in SO group compared with Sham group (**P < 0.01), and
SO þ CA group exhibited signiﬁcantly higher serum calcium content, relative to SO
group (#P < 0.05). (B) Urine calcium: SO group exhibited higher urinary calcium
excretion compared with Sham group (**P < 0.01). SO þ CA group exhibited signiﬁ-
cantly lower urinary calcium excretion, relative to SO group (#P < 0.05). The data are
expressed as means ± SEM.
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experimental mice
We further investigated several serum markers of bone meta-
bolism among three groups. Signiﬁcant decreases in serum con-
centrations of PTH and TRAP-5b were seen following celastrol
treatment, but ALP-b serum concentrations did not differ signiﬁ-
cantly between SO group and SO þ CA group (Fig. 3AeC). More
interestingly, collagen C-terminal telopeptide (CTX) and deoxy-
pyridinoline (DPD), the serum markers of cartilage metabolism,
were also signiﬁcantly reduced with celastrol treatment in SO
group (Fig. 3D and E). Above results suggested that celastrol
treatment led to striking improvement in bone metabolism, as well
as in cartilage metabolism.3.4. Effects of celastrol on articular cartilage in experimental mice
Based on the known effect of celastrol on improving bone
metabolism, H&E and safranin-O staining were performed to
assess bone structure in mice with secondary osteoporosis. As
shown in Fig. 4A, safranin-O staining of articular cartilage wasFig. 3. Concentrations of serum PTH (A), ALP-b (B), TRAP-5b (C), CTX (D) anreduced in secondary osteoporosis group, while celastrol treat-
ment enhanced the staining. Likewise, H&E staining revealed the
degradation of cancellous bone in proximal tibia metaphysis in
mice with secondary osteoporosis, however, celastrol led to
obvious amelioration of cancellous bone degradation. Moreover,
the bone structure scores exhibited a parallel trend as the
staining results among three groups. SO þ CA group got a much
lower structure score of articular cartilage than SO group, as well
as of cancellous bone (Fig. 4B). Furthermore, safranin-O staining
revealed chondrocytes hypertrophy in SO group, but celastrol
displayed compelling amelioration of cellular abnormality and
irregularity, which was further conﬁrmed through cell score
(Fig. 5). Our results indicated that celastrol treatment led to
compelling amelioration of articular cartilage lesions in mice
with secondary osteoporosis.3.5. Effects of celastrol on proteins involved in cartilage metabolism
in experimental mice
To further conﬁrm the effects of celastrol on articular cartilage in
experimental mice subjected to secondary osteoporosis, levels ofd DPD (E) in experimental mice. Data are shown as the means ± SEM.
Fig. 4. Histological evaluation of bone structure after treatment with celastrol in experimental mice. (A) Safranin-O staining of articular cartilage, and H&E staining of
cancellous bone in proximal tibia metaphysis per group. The articular cartilage staining was reduced in secondary osteoporosis group. (B) Structure score of articular cartilage
(AC) and cancellous bone in proximal tibia metaphysis (PTM). Bone structure was graded using Mankin scoring system. The data are expressed as means ± SEM. SO group got
signiﬁcantly higher structure scores of AC and PTM than Sham group (P < 0.01). SO þ CA group got much lower structure scores of AC and PTM than SO group (P ¼ 0.03,
P ¼ 0.025).
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MMP-1, and MMP-9, were investigated among three groups.
Obviously, NF-kB (P65), MMP-1, and MMP-9 levels in SO group
were much higher than Sham group, but signiﬁcant decline in
levels of these proteins were observed following celastrol treat-
ment (Fig. 6A and B).4. Discussion
Current knowledge on the pathogenesis of osteoporosis
suggested a potential role of inﬂammatory response in the
progression of secondary osteoporosis. NF-kB, a key factor in
inﬂammatory system, is responsible for the expression of genes
that are involved in inﬂammatory reaction. Till now, a great deal
of evidences have revealed the beneﬁcial effect of direct inhi-
bition of NF-kB on inﬂammatory disease (37,38), thereby, in this
study, we assessed body weight, body fat, serum and urinary
calcium, serum markers of bone metabolism, and morphological
changes in bone structure in a mouse model of secondaryosteoporosis induced by dexamethasone, after celastrol treat-
ment. We observed marked decreases in body weight and body
fat in mice with secondary osteoporosis after celastrol treat-
ment, and also a signiﬁcant increase in leptin level. The possi-
bility of signiﬁcant weight loss is reduced food consumption
after celastrol treatment (33). Leptin is presumably to activate
hypothalamic NF-kB and modulate the transcription of leptin-
stimulated POMC, thus, regulated lipid metabolism (39).
Decreased body weight in illness-and leptin-induced anorexia
has been reported to be mediated through NF-kB activation in
hypothalamic pro-opiomelanocortin (POMC) neurons (40).
Additionally, in this study, we conﬁrmed the direct effect of
leptin on body weight and body fat in experimental mice after
celastrol administration, strongly indicating that celastrol exer-
ted clear effects on regulating abnormal lipid metabolism in
mice subjected to secondary osteoporosis, through affecting
leptin expression.
Urinary excretion of bone-seeking labels, which is more
practical and precise than biomarkers, provides a novel insight
Fig. 5. Effects of celastrol on chondrocytes in experimental mice, and cell score was performed to assess chondrocytes through Mankin scoring system. Data are expressed as the
means ± SEM.
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assessing bone turnover, considering that they are more effective
in labeling the skeleton (42), as well as are easily reabsorbed into
newly forming bone (43). Thus, urinary calcium excretion is
responsive to the changes in bone turnover. As elevated urinary
calcium frequently occurs in osteoporotic subjects, especially in
postmenopausal women with osteoporosis (7), in this study, we
further found that celastrol treatment in experimental mice with
secondary osteoporosis led to signiﬁcant improvement in
hypercalciuria, and also in hypercalcemia, but notable changes in
serum calcium between SO group and SO þ CA group belonged
to the normal ﬂuctuation range, indicating, hypercalciuria, a
promising indicator of secondary osteoporosis for clinical ther-
apy, is dramatically ameliorated after celastrol treatment.
On the other hand, we also found signiﬁcant decline in serum
concentrations of PTH, TRAP-5b, CTX and DPD, the commonly
used serum bone markers, in experimental mice with secondary
osteoporosis after celastrol treatment, indicating the ameliora-
tive effect of celastrol on abnormal bone metabolism in sec-
ondary osteoporosis. Osteoblasts are in charge of bone formation
and osteoclasts for its resorption, and the balance of bone
metabolism is sustained through the coordination of these two.
Changes in serum bone markers not only predict the response in
bone metabolism (44), but also can be detected earlier than al-
terations in bone mineral density (BMD) (45). Many studies haveaddressed the relevance between serum markers of bone meta-
bolism and osteoporosis. In the U.S., Australia, even Europe, they
have started intermittent PTH injection to excite bone formation
(46). Actually, the use of PTH in therapy for osteoporosis has
already been established (47). In our study, H&E and safranin-O
staining also revealed compelling amelioration of articular
cartilage lesions and degradation of cancellous bone in mice with
secondary osteoporosis after celastrol treatment. It was previ-
ously reported that microstructural alterations of articular
cartilage were closely related to the progression of osteoporosis,
and also osteoarthritis (48). Furthermore, celastrol exhibited
chondroprotective properties in a mouse model of secondary
osteoporosis. Following a recent study, decreased MMP expres-
sion is associated with NF-kB signaling pathway in human
osteoarthritic chondrocytes (49). Our study demonstrated that
the expression of NF-kB (P65), MMP-1, and MMP-9 were all
signiﬁcantly reduced with celastrol treatment in experimental
mice with secondary osteoporosis.
In summary, celastrol not simply exhibited dramatic amelio-
ration of disordered lipid metabolism and hypercalciuria in a
mouse model of secondary osteoporosis induced by dexametha-
sone, but also mitigates articular cartilage lesions, both in cartilage
tissues and chondrocytes. Our results strongly implicate NF-kB as a
novel therapeutic target in the future treatment of secondary
osteoporosis.
Fig. 6. Effects of celastrol on the expression of NF-kB (P65), MMP-1, and MMP-9 in
experimental mice (A) Protein levels of NF-kB (P65), MMP-1, and MMP-9 were
determined by western blot, and b-actin served as internal control. (B) mRNA levels of
NF-kB (P65), MMP-1, and MMP-9 were determined by qRT-PCR. GAPDH was used as
internal control. The data are shown as means ± SEM. *indicates a statistically sig-
niﬁcant difference between Sham group and SO group (P < 0.05). #indicates a sta-
tistically signiﬁcant difference between SO group and SO þ CA group (P < 0.05).
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